192 related articles for article (PubMed ID: 11707845)
41. De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission.
Wong BY; Ma Y; Fitzwilson R; Dang NH
Am J Hematol; 2008 Jul; 83(7):596-8. PubMed ID: 18383317
[TBL] [Abstract][Full Text] [Related]
42. E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study.
Ohmachi K; Ando K; Ogura M; Uchida T; Tobinai K; Maruyama D; Namiki M; Nakanishi T
Cancer Sci; 2018 Mar; 109(3):794-802. PubMed ID: 29363235
[TBL] [Abstract][Full Text] [Related]
43. Interleukin-2 receptor-directed therapies for cutaneous lymphomas.
Foss FM; Waldmann TA
Hematol Oncol Clin North Am; 2003 Dec; 17(6):1449-58. PubMed ID: 14710895
[TBL] [Abstract][Full Text] [Related]
44. Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy.
Park M; Liu GT; Piltz-Seymour J; Wisda CL; Rook AH; Junkins-Hopkins JM; Nasta SD; Kim EJ
Leuk Lymphoma; 2007 Apr; 48(4):808-11. PubMed ID: 17454642
[No Abstract] [Full Text] [Related]
45. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
Frankel AE; Fleming DR; Hall PD; Powell BL; Black JH; Leftwich C; Gartenhaus R
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3555-61. PubMed ID: 14506141
[TBL] [Abstract][Full Text] [Related]
46. Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy.
Paschal BR
Leuk Lymphoma; 2003 Apr; 44(4):731-3. PubMed ID: 12769354
[TBL] [Abstract][Full Text] [Related]
47. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.
Foss FM; Borkowski TA; Gilliom M; Stetler-Stevenson M; Jaffe ES; Figg WD; Tompkins A; Bastian A; Nylen P; Woodworth T
Blood; 1994 Sep; 84(6):1765-74. PubMed ID: 8080984
[TBL] [Abstract][Full Text] [Related]
48. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides.
Ghori F; Polder KD; Pinter-Brown LC; Hoff AO; Gagel RF; Sherman SI; Duvic M
J Clin Endocrinol Metab; 2006 Jun; 91(6):2205-8. PubMed ID: 16595600
[TBL] [Abstract][Full Text] [Related]
49. Denileukin diftitox: a novel immunotoxin.
Manoukian G; Hagemeister F
Expert Opin Biol Ther; 2009 Nov; 9(11):1445-51. PubMed ID: 19817678
[TBL] [Abstract][Full Text] [Related]
50. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma.
Kawai H; Ando K; Maruyama D; Yamamoto K; Kiyohara E; Terui Y; Fukuhara N; Miyagaki T; Tokura Y; Sakata-Yanagimoto M; Igarashi T; Kuroda J; Fujita J; Uchida T; Ishikawa T; Yonekura K; Kato K; Nakanishi T; Nakai K; Matsunaga R; Tobinai K
Cancer Sci; 2021 Jun; 112(6):2426-2435. PubMed ID: 33792128
[TBL] [Abstract][Full Text] [Related]
51. DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology.
Foss FM
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S27-31. PubMed ID: 11707860
[TBL] [Abstract][Full Text] [Related]
52. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.
Knueppel A; Lange S; Altmann S; Sekora A; Knuebel G; Vogel H; Lindner I; Freund M; Junghanss C
Vet Immunol Immunopathol; 2012 Jan; 145(1-2):233-40. PubMed ID: 22173275
[TBL] [Abstract][Full Text] [Related]
53. Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.
Telang S; Rasku MA; Clem AL; Carter K; Klarer AC; Badger WR; Milam RA; Rai SN; Pan J; Gragg H; Clem BF; McMasters KM; Miller DM; Chesney J
BMC Cancer; 2011 Dec; 11():515. PubMed ID: 22165955
[TBL] [Abstract][Full Text] [Related]
54. The IL-2 diphtheria toxin fusion protein denileukin diftitox modulates the onset of diabetes in female nonobese diabetic animals in a time-dependent manner and breaks tolerance in male nonobese diabetic animals.
Zinser E; Rössner S; Littmann L; Pangratz N; Schuler G; Steinkasserer A
J Immunol; 2012 Aug; 189(3):1173-81. PubMed ID: 22730534
[TBL] [Abstract][Full Text] [Related]
55. Durable complete remission of therapy-refractory, tumor-stage cutaneous T-cell lymphoma under radioimmunotherapy with electron beam irradiation and denileukin diftitox.
Wobser M; Göppner D; Lang SC; Beckmann G; Flentje M; Ugurel S; Bröcker EB; Becker JC
Arch Dermatol; 2010 Jul; 146(7):805-6. PubMed ID: 20644054
[No Abstract] [Full Text] [Related]
56. Bilateral adrenal hemorrhage and adrenal insufficiency in a patient with lymphomatous adrenal infiltration following administration of a fusion toxin (DAB486 interleukin-2).
Cohen R; Jaffe ES; Stetler-Stevenson MA; Sausville EA; DeNigris EC; Woodworth T; Foss FM
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):229-33. PubMed ID: 7834123
[TBL] [Abstract][Full Text] [Related]
57. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Duvic M
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
[TBL] [Abstract][Full Text] [Related]
58. A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development.
Scheinfeld N
J Drugs Dermatol; 2007 Jul; 6(7):757-60. PubMed ID: 17763605
[TBL] [Abstract][Full Text] [Related]
59. Choices in the treatment of cutaneous T-cell lymphoma.
Hymes KB
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):18-23. PubMed ID: 17474355
[TBL] [Abstract][Full Text] [Related]
60. Optimal combination with PUVA: rationale and clinical trial update.
Stadler R
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):29-32. PubMed ID: 17474357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]